SCHEMBL8406002

SCHEMBL8406002

O=C1/C(=N\Cc2ccc(Oc3ccccc3)cc2)c2ccccc2N1c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
MEN1 O00255 2/20 0.53
MAPT P10636 6/20 0.51
NPSR1 Q6W5P4 3/20 0.51
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
LMNA P02545 1/20 0.46
CES2 O00748 1/20 0.46
BCHE P06276 1/20 0.46
GAA P10253 1/20 0.46
CES1 P23141 1/20 0.46
ACE P12821 2/20 0.43
GALR3 O60755 3/20 0.42
HTR4 Q13639 1/20 0.42
MGLL Q99685 1/20 0.41
NR1H3 Q13133 1/20 0.39
CHRM5 P08912 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8226920 0.85 KMT2A (0.52) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL917365 0.81 GALR3 (0.56) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL917367 0.81 GALR3 (0.56) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL12942336 0.80 KMT2A (0.52) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL8410768 0.78 KMT2A (0.50) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL8404173 0.77 KMT2A (0.50) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL8404175 0.75 MAPT (0.47) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL8405541 0.74 KMT2A (0.44) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL12938088 0.73 ALDH1A1 (0.65) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL13086556 0.70 MAPT (0.64) KMT2AMEN1MAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030078271-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods SYNAPTIC PHARMACEUTICAL CORPORATION 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078271-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR2, GALR1 KMT2A 4393/4885MEN1 4213/4885MAPT 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.